Atara Biotherapeutics
ATRA
ATRA
125 hedge funds and large institutions have $298M invested in Atara Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 52 increasing their positions, 42 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
6% less capital invested
Capital invested by funds: $316M → $298M (-$18.6M)
10% less funds holding
Funds holding: 139 → 125 (-14)
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
Holders
125
Holding in Top 10
1
Calls
$4.86M
Puts
$77K
Top Buyers
| 1 | +$3.69M | |
| 2 | +$2.9M | |
| 3 | +$2.48M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.43M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.02M |
Top Sellers
| 1 | -$1.97M | |
| 2 | -$1.83M | |
| 3 | -$1.51M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.03M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$894K |